News

How Cancer Biologists and Infectious Disease Immunologists Can Learn From Each Other
January 19th, 2017

The yin-yang of cancer and infectious disease  

Read more

On the importance of fundamental research
July 8th, 2016

In a podcast, hosted by the Journal of Immunology, Professor David H. Raulet discusses the importance of fundamental research. The podcast is available here, and refers to a Pillars of Immunology article published previously by David Raulet, highlighting a pair of classic 1971 articles by Cudkowicz and Bennett. The article and podcast provide yet another example of how […]

Read more

June is Cancer Immunotherapy Month
June 15th, 2016

With our close partners at the Cancer Research Institute, the CRL is pleased to highlight June as Cancer Immunotherapy Month. The past year has seen immunotherapy ever more in the news. For example, in March of this year, Jimmy Carter announced that immunotherapy had successfully treated his melanoma. And in January, spurred on in large part […]

Read more

From food poisoning to cancer immunotherapy
March 9th, 2016

How has research at UC Berkeley on a soil bacterium called Listeria monocytogenes led to new approaches to cancer treatment? The Cancer Research Lab is founded on the belief that fundamental research can lead to novel and entirely unexpected approaches to cancer therapy. This belief is exemplified by the remarkable story of how research in Professor […]

Read more

Immunotherapeutics and Vaccine Research Initiative (IVRI)
March 7th, 2016

The CRL and CEND (The Center for Emerging and Neglected Diseases) are joining forces to help launch a new campus initiative. The new initiative is called the Immunotherapeutics and Vaccine Research Initiative or IVRI, and is being launched officially on March 24-25, 2016 to coincide with a Symposium on Immunotherapy on the UC Berkeley campus. […]

Read more

CEND/IVRI Symposium on Immunotherapy at UC Berkeley
March 7th, 2016

The CRL is joining forces with two campus organizations to sponsor an exciting new Symposium at UC Berkeley on Immunotherapy. The CRL will join the Henry Wheeler Center for Emerging & Neglected Diseases (CEND) and the new Immunotherapeutics and Vaccine Research Initiative (IVRI) to sponsor a Symposium that aims to strengthen connections between scientists working […]

Read more

Lasker Award for CRL Immunotherapy Research
September 8th, 2015

Congratulations to former CRL Director James P. Allison for winning the 2015 Lasker-DeBakey Clinical Medical Research Award. The Lasker Committee recognized Dr. Allison’s groundbreaking work on immunotherapy of cancer, specifically citing “the discovery and development of a monoclonal antibody therapy that unleashes the immune system to combat cancer.” The work recognized by the Lasker Award […]

Read more

June is Cancer Immunotherapy Month
June 1st, 2015

The UC Berkeley Cancer Research Lab is joining the Cancer Research Institute to promote June as Cancer Immunotherapy Month. The Cancer Research Laboratory (CRL) at UC Berkeley has played a key role in the development of novel cancer immunotherapies. In particular the idea of checkpoint blockade was developed by Prof James Allison when he was Director of […]

Read more

Berkeley leading the way on new approaches to cancer immunotherapy
March 30th, 2015

A newly announced biotech deal shows how basic research at UC Berkeley is leading to new therapeutic approaches for cancer. Novartis has just announced a major $750M partnership with Berkeley-based Aduro BioTech to develop a new class of molecules, called CDNs, as a potential immunotherapy for cancer. These molecules were first discovered in bacteria, but the […]

Read more

CRL researchers identify a new approach to cancer immunotherapy
March 16th, 2015

David Raulet’s lab, affiliated with the UC Berkeley Cancer Research Laboratory, has published a new paper in Science. The new research, published online on March 5, suggests a new approach to cancer immunotherapy, and pertains to a special class of immune cells called Natural Killer cells.  These cells normally patrol the body, seeking out abnormal cells […]

Read more

CRL collaborators on new $4.3M grant awarded to study the brain
September 30th, 2014

The Cancer Research Lab is proud announce we are collaborators on a new $4.3M grant from the National Institutes of Health. The grant was awarded to CRL affiliated faculty member Prof John Ngai and a team of associated researchers. The new research will help identify and characterize neuronal cell types in the brain. The CRL will participate […]

Read more

Scientist’s Drive Puts the Brakes on Cancer
September 11th, 2014

The Association of University Technology Managers (AUTM) has posted an article describing Jim Allison’s work in the CRL. The article describes how Jim’s work in the Cancer Research Lab at UC Berkeley led to a novel FDA-approved therapy for melanoma: As a kid, James Allison loved to figure out how things worked. “I wanted to […]

Read more

Single Cell Western Blotting
July 24th, 2014

The Herr and Schaffer labs at UC Berkeley describe the development of a new technology called Single Cell Western Blotting. This new technology, which allows for unprecedented analysis of protein expression at the single cell level, was developed in conjunction with Dr. Kartoosh Heydari at the CRL Flow Cytometry Facility. For more information see http://www.ncbi.nlm.nih.gov/pubmed/24880876.

Read more

Berkeley Professors newly elected to the National Academy of Sciences
May 20th, 2014

The CRL would like to congratulate the five Berkeley faculty that have been newly elected to the National Academy of Sciences, one of the highest national honors that can be bestowed to a scientist. We would particularly like to congratulate our own Richard Harland

Read more

Jim Allison confronts cancer, critics with immunotherapy
April 16th, 2014

The San Francisco Chronicle published a profile on Jim Allison, who performed much of his breakthrough cancer research in the Cancer Research Laboratory at UC Berkeley.

Read more

CRL Researchers show how MicroRNAs protect against tumors
March 1st, 2014

Two new papers published by Cancer Research Laboratory scientists have shown how unique cellular regulators called “microRNAs” can protect against tumors. The first paper, published by the laboratory of Prof. Lin He in the journal Genes & Development, shows how a particular microRNA called miR-34 can induce the important tumor suppressor gene p53. This effect […]

Read more

Breakthrough Of The Year
December 20th, 2013

The editors of Science magazine have chosen Cancer Immunotherapy as their Breakthrough of the Year for 2013. The magazine cover image features work done in the Cancer Research Laboratory at Berkeley in the 1990s by Jim Allison and colleagues. See the December 20th issue of Science for more details or read about the groundbreaking cancer […]

Read more

Yervoy (Ipilimumab)
November 21st, 2013

In the late 1990s, while serving as the Director of the UC Berkeley Cancer Research Laboratory, Jim became intrigued by a special biological molecule called CTLA-4. This molecule was displayed on the surface of particular cells in the immune system called T cells. Jim and his colleagues — most notably, graduate student Max Krummel, and […]

Read more

Back to Top